GSA Capital Partners’s ADC Therapeutics ADCT Stock Holding History
Bought
Maintained
Sold
Other funds holding ADCT
ACM
OM
GSA Capital Partners's ADCT Position: Q3 2026 in Review
GSA Capital Partners increased its ADC Therapeutics (ADCT) stake by 80% in Q3 2026, buying an estimated $51.1K and bringing the position to 98,413 shares worth $120K. The position accounts for 0.01% of the portfolio, ranked #1685.
GSA Capital Partners first reported a position in ADCT in Q1 2023 and has held it in 6 quarters since. The position peaked at $234K in Q2 2023. 110 funds tracked by Wall St. Rank hold ADCT as of Q3 2026.
- GSA Capital Partners held 98,413 shares of ADC Therapeutics worth $120K as of Q3 2026.
- GSA Capital Partners bought 43,718 ADC Therapeutics shares in Q3 2026, an estimated $51.1K.
- ADC Therapeutics made up 0.01% of GSA Capital Partners's portfolio in Q3 2026, its #1685 holding.
- GSA Capital Partners first reported a position in ADC Therapeutics in Q1 2023 and has held it in 6 quarters since.
- GSA Capital Partners's ADC Therapeutics position peaked at $234K in Q2 2023.
- 110 funds tracked by Wall St. Rank held ADC Therapeutics as of Q3 2026.
Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.